Fate Therapeutics Inc Share Price Today: Live Updates & Key Insights

Fate Therapeutics Inc share price today is $1.12, up 1.85%. The stock opened at $1.09 against the previous close of $1.08, with an intraday high of $1.12 and low of $1.065.

Fate Therapeutics Inc Share Price Chart

Fate Therapeutics Inc

us-stock
To Invest in {{usstockname}}
us-stock

Fate Therapeutics Inc Share Price Performance

$1.12 0.0185(1.85%) FATE at 23 Mar 2026 12:59 PM Biotechnology
Lowest Today 1.065
Highest Today 1.12
Today’s Open 1.09
Prev. Close 1.08
52 Week High 1.94
52 Week Low 0.66
Day’s Range: Low 1.065 High 1.12
52-Week Range: Low 0.66 High 1.94
1 day return -
1 Week return -4.72
1 month return -26.97
3 month return +5.21
6 month return +10.44
1 year return +17.23
3 year return -78.4
5 year return -98.79
10 year return -

Fate Therapeutics Inc Institutional Holdings

Redmile Group, LLC 11.07

BlackRock Inc 9.19

Vanguard Group Inc 7.72

Wilshire Advisors 7.30

Johnson & Johnson 2.91

Vanguard Total Stock Mkt Idx Inv 2.56

Acadian Asset Management LLC 2.33

iShares Russell 2000 ETF 2.26

Vanguard Strategic Equity Inv 2.19

Geode Capital Management, LLC 2.12

State Street Corp 2.08

Renaissance Technologies Corp 2.03

TANG CAPITAL MANAGEMENT LLC 1.61

Two Sigma Investments LLC 1.49

Vestal Point Capital LP 1.48

Two Sigma Advisers, LLC 1.42

Dimensional Fund Advisors, Inc. 1.36

The Goldman Sachs Group Inc 1.28

AQR Capital Management LLC 1.00

Vanguard Institutional Extnd Mkt Idx Tr 0.92

Fidelity Small Cap Index 0.91

Morgan Stanley - Brokerage Accounts 0.80

iShares Russell 2000 Value ETF 0.78

BlackRock Advantage Small Cap Core Instl 0.76

Jane Street Group LLC 0.72

Northern Trust Corp 0.70

Charles Schwab Investment Management Inc 0.67

Bruce 0.63

State St Russell Sm/Mid Cp® Indx SL Cl I 0.55

Vanguard Russell 2000 ETF 0.45

Schwab US Small-Cap ETF™ 0.44

Fidelity Extended Market Index 0.32

Vanguard Strategic Small-Cap Equity Inv 0.31

DFA US Targeted Value I 0.29

State St Russell Sm Cap® Indx SL Cl I 0.27

Vanguard Market Neutral I 0.27

Invesco RAFI US 1500 Small-Mid ETF 0.26

Vanguard Health Care ETF 0.26

iShares Micro-Cap ETF 0.24

Schwab Small Cap Index 0.23

Fate Therapeutics Inc Market Status

Strong Buy: 3

Buy: 2

Hold: 7

Sell: 0

Strong Sell: 0

Fate Therapeutics Inc Fundamentals

Market Cap 127.89 M

PB Ratio 0.6201

PE Ratio 0.0

Enterprise Value 2.67 M

Total Assets 318.94 M

Volume 3469255

Fate Therapeutics Inc Company Financials

Annual Revenue FY25:6646000 6.6M, FY23:106213000 106.2M, FY22:96300000 96.3M, FY21:55846000 55.8M, FY20:31434000 31.4M

Annual Profit FY25:null 0.0M, FY23:null 0.0M, FY22:96300000 96.3M, FY21:55846000 55.8M, FY20:31434000 31.4M

Annual Net worth FY25:-136315000 -136.3M, FY23:-173169000 -173.2M, FY22:-255056000 -255.1M, FY21:-206301000 -206.3M, FY20:-170300000 -170.3M

Quarterly Revenue Q4/2025:1369000 1.4M, Q3/2025:1741000 1.7M, Q2/2025:1907000 1.9M, Q1/2025:1629000 1.6M, Q3/2024:3074000 3.1M

Quarterly Profit Q4/2025:-5277000 -5.3M, Q3/2025:1741000 1.7M, Q2/2025:1907000 1.9M, Q1/2025:1629000 1.6M, Q3/2024:3074000 3.1M

Quarterly Net worth Q4/2025:-32374000 -32.4M, Q3/2025:-32250000 -32.3M, Q2/2025:-34070000 -34.1M, Q1/2025:-37621000 -37.6M, Q3/2024:-47678000 -47.7M

About Fate Therapeutics Inc & investment objective

Company Information Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex autoimmune diseases; and FT825 to treat solid tumors. It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. The company was incorporated in 2007 and is headquartered in San Diego, California.

Organisation Biotechnology

Employees 161

Industry Biotechnology

CEO Dr. Bahram Valamehr M.B.A., Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Fate Therapeutics Inc FAQs

What is the share price of Fate Therapeutics Inc today?

The current share price of Fate Therapeutics Inc is $1.12.

Can I buy Fate Therapeutics Inc shares in India?

Yes, Indian investors can buy Fate Therapeutics Inc shares by opening an international trading and demat account with Motilal Oswal.

How to buy Fate Therapeutics Inc shares in India?

You can easily invest in Fate Therapeutics Inc shares from India by:

Can I buy fractional shares of Fate Therapeutics Inc?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Fate Therapeutics Inc?

Fate Therapeutics Inc has a market cap of $127.89 M.

In which sector does Fate Therapeutics Inc belong?

Fate Therapeutics Inc operates in the Biotechnology sector.

What documents are required to invest in Fate Therapeutics Inc stocks?

To invest, you typically need:

What is the PE and PB ratio of Fate Therapeutics Inc?

The PE ratio of Fate Therapeutics Inc is N/A and the PB ratio is 0.62.